Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005312 | 0.94 | TSHR (0.56) | TSHRALDH1A1LMNACA12CA14 | |
| SCHEMBL222756 | 0.92 | TSHR (0.54) | TSHRALDH1A1LMNACA12CA14 | |
| SCHEMBL7003583 | 0.92 | TSHR (0.54) | TSHRALDH1A1LMNACA12CA14 | |
| SCHEMBL841503 | 0.86 | — | — | |
| SCHEMBL5651628 | 0.82 | CYP1A2 (0.52) | TSHRALDH1A1EPHX2KMT2ASMN1; SMN2 | |
| SCHEMBL27312215 | 0.77 | TSHR (0.56) | TSHRALDH1A1LMNACA12CA14 | |
| SCHEMBL14430277 | 0.77 | TSHR (0.70) | TSHRALDH1A1LMNACA12CA14 | |
| SCHEMBL8176275 | 0.76 | CYP1A2 (0.50) | TSHRALDH1A1EPHX2KMT2A | |
| SCHEMBL21538522 | 0.76 | TSHR (0.61) | TSHRALDH1A1LMNACA12CA14 | |
| SCHEMBL14975 | 0.75 | TSHR (0.88) | TSHRALDH1A1LMNACA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | disclosed |
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1081149-B1 | PYRAZOLO 1,5-a]PYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| EP-0925299-B1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-6372749-B1 | PHARMACOLOGICAL EFFECTS SUCH AS ANALGESIC ACTION, INHIBITORY EFFECT ON NITROGEN MONOXIDE SYNTHETASE AND THE LIKE AND ARE USEFUL AS ANALGESICS. | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2002-04-16 | — | — | US | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0436902-A1 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | TSHR 499/4885ALDH1A1 1438/4885LMNA 4146/4885 |
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | TSHR 2490/4885ALDH1A1 228/4885LMNA 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.